Treatments for Drug-resistant Epilepsy: An Update
Wednesday April 26, 2017 3:30 pm to 5:30 pm
Epilepsy/Clinical Neurophysiology (EEG)
Ellen Bubrick MD
Epilepsy is a common neurologic disorder, and up to a third of patients suffer from drug-resistant disease. This course will define this patient population using the most current classification system, and then focus on available treatment options including surgical resection, devices, and other non-traditional approaches. The discussion of surgery will be broken down into indications for resection with and without invasive monitoring, intracranial monitoring techniques (e.g., subdural electrodes vs. stereoEEG), and the use of laser ablation. The devices section will cover good candidates for vagal nerve stimulators as well as when to consider responsive neuro-stimulation, and current data on the latter. Other available treatments including data on diet therapies and cannabinoids will briefly be discussed.
Participants should be able to identify patients with drug-resistant epilepsy, become familiar with current treatment options for this patient population, and know when to refer these patients for surgery or other treatment options.
Medical Knowledge, Patient Care
Program Speakers - Tentative
3:30 PM - 4:00 PM
Drug-resistant Epilepsy: What Is It? Who Has It? How to Treat It?
Ellen Bubrick MD
4:00 PM - 4:30 PM
Surgical Management of Drug-resistant Focal Epilepsy
Gregory D. Cascino MD, FAAN
4:30 PM - 5:00 PM
Case Studies in Surgical Epilepsy
G. Rees Cosgrove MD, FRCS(C)
5:00 PM - 5:30 PM
Questions and Answers
Ellen Bubrick, MD
Dr. Bubrick has nothing to disclose.
Gregory D. Cascino, MD, FAAN
Dr. Cascino has received personal compensation in an editorial capacity for American Academy of Neurology and the journal Neurology. Dr. Cascino holds stock and/or stock options in Nevro through Mayo Medical ventures.
G. Rees Cosgrove, MD, FRCS(C)
Dr. Cosgrove has nothing to disclose.
Ready to register for the 2018 AAN Annual Meeting?